Spot the differences:

Our independent registered public accounting firm, Semple, Marchal & Cooper, LLP, state in their audit report attached to our audited consolidated financial statements for the fiscal years that ended January 31, 2007 and 2006 that since we are an exploration stage company, have no established source of revenue and are dependent on our ability to raise capital from shareholders or other sources to sustain operations, there is a substantial doubt that we will be able to continue as a going concern.

On May 22, 2007, we announced that it has closed on a private equity investment in the Company totaling approximately $13.5 million. The investors received Pluristem-restricted Common Stock at a price of $0.0125 per share and a Warrant to purchase additional shares at an exercise price of $0.025 per share. Additionally, on April 4, 2007, the Company announced that as of Friday, March 30, 2007, it had received approximately $1 million from the exercise of approximately 15 million Warrants at an exercise price of $0.075. This represents exercise of more than 25% of our outstanding listed Warrants as of March 30, 2007. Our ability to continue to develop the PluriX™ Bioreactor System and commercialize our potential cell therapy products is dependent upon our ability to raise significant additional financing when needed. If the Company is unable to obtain such financing, we will not be able to fully develop our technology and commercialize our cell therapy products. Our future capital requirements will depend upon many factors, including

Liquidity and Capital Resources

During the year ended June 30, 2007, we incurred a net loss of $8,428,900, as compared to a net loss of $2,439,724 in the year ended June 30, 2006. The net loss includes stock based compensation to employees and consultants of $3,305,874 during the year ended June 30, 2007, as compared to an amount of $114,800 in the year ended June 30, 2006 and an expense in the amount of $1,962,500 regarding the Assignment Agreement dated May 15, 2007. This resulted from moving forward with our research and development plan. We obtained funds to carry on our business from private placements we conducted in October of 2004 and January of 2005, which raised gross proceeds of approximately $3,250,000 through the issuance of 32,500,000 units comprising one common share and one common share purchase warrants. On April 3, 2006 we raised gross proceeds of approximately $3,000,000 through the issuance of senior secured convertible debentures. On March and April 2007, we received approximately $1 million from the exercise of approximately 15 million Warrants related to the April 3, 2006 issuance. On May 14, 2007, we closed a private placement consisting of 1,080,000,000 units of our securities at a price of $0.0125 per unit for gross proceeds of $13,500,000. Each unit consists of one common share in the capital of our company and one common share purchase warrant, with one such warrant entitling the holder to purchase one share of our common stock at a price of $0.025 per share for a period of five years. Of the $13,500,000, we have received all but $5,075,000, of which $5,000,000 is being paid in monthly installments over 10 months starting six months from closing. As at June 30, 2007 we had cash of $1,653,087 and marketable securities in the value of $ 3,758,327.

While we expect that we have sufficient funds to operate until early summer of 2008, we will have to raise additional funds from the market before we have any cash flow from operations. We believe that it will take several years for us to complete the approval process for our products in the United States or any other jurisdiction. In addition, future decisions regarding any acquisitions that we may choose to make or product development that is beyond the scope of what is described in our Plan of Operations will require additional capital, which must be raised through the issuance additional securities and/or incurring more debt.

http://www.pinksheets.com/edgar/GetF...

Apples and oranges?

Be well